Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:63ffcfb8048b1b6b0530df9bc82836ab]
Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Occurrence of dose limiting toxicity (DLT) During the study period (until Week 40 or 43) and the post-study follow-up period (5 years) [clinicaltrials_resource:63ffcfb8048b1b6b0530df9bc82836ab]
Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
Bio2RDF identifier
63ffcfb8048b1b6b0530df9bc82836ab
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:63ffcfb8048b1b6b0530df9bc82836ab
measure [clinicaltrials_vocabulary:measure]
Occurrence of dose limiting toxicity (DLT)
time frame [clinicaltrials_vocabulary:time-frame]
During the study period (until ...... udy follow-up period (5 years)
description
Six doses of dHER2 (20 µg) + AS15 administered at Weeks 0, 2, 4, 6, 10 and 14.
identifier
clinicaltrials_resource:63ffcfb8048b1b6b0530df9bc82836ab
title
Occurrence of dose limiting to ...... udy follow-up period (5 years)
@en
type
label
Occurrence of dose limiting to ...... fcfb8048b1b6b0530df9bc82836ab]
@en